Tenaya Therapeutics (NASDAQ: TNYA) reported interim data from its RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for adults ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE